Tags: Drug.

Suvorexant (MK-4305) is a dual orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It is not currently approved for commercial use but it has completed three Phase III trials. Results look promising.

MK4305_structure.png
ATC prefix
None
CAS number
1030377-33-3
IUPAC name
[(7R)-4-(5-chloro-13-benzoxazol-2-yl)-7-methyl-14-diazepan-1-yl][5-methyl-2-(2H-123-triazol-2-yl)phenyl]methanone
PubChem
24965990

Loading...

This page contains content from the copyrighted Wikipedia article "Suvorexant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.